AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

846.233

+14.1041.69%

Number of Gainers:13

Number of Losers:12

Number of Flat:20

PE:- -

High:847.992

Open:828.860

Low:828.659

Close:832.129

Loading ...

Orthocell Ltd - Seeks Trading Halt Pending Announcement on New Regulatory Approval for Remplir

THOMSON REUTERS

Mesoblast Appoints Corporate Finance Leader Lyn Cobley to Board

THOMSON REUTERS

Press Release: Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

Medical Developments International Ltd - Group Revenue for Q3 FY25 Was a$8.9 Mln

THOMSON REUTERS

Dimerix - Seeks Trading Halt Pending Announcement on Licensing Agreement

THOMSON REUTERS

3 ASX 200 stocks to buy and hold forever without thinking twice

ASX Stocks Estimated Below Intrinsic Value In April 2025

Simply Wall St.

How Trump's tariffs have created 'upside potential' for CSL shares

BUZZ-Australia's Orthocell advances on product approval in Thailand

Orthocell Secures License to Sell Nerve Repair Treatment in Thailand

MT Newswires Live

Orthocell Ltd -Remplir Approved to Commence Sales

THOMSON REUTERS

Orthocell Ltd - Remplir Is NOW Approved in US, Australia, New Zealand, Singapore and Thailand

THOMSON REUTERS

Why buy and hold investing with ASX shares could be your smartest move yet

The 2025 stock market selloff could be a once-in-a-decade opportunity to build wealth

3 oversold ASX shares begging to rebound

NewMarket Greenlights $100 Million AMPAC Expansion; Maintains Dividend

MT Newswires Live

ASX Penny Stocks To Watch In April 2025

Simply Wall St.

Warren Buffett's warning to markets played out perfectly: the time to be greedy may be approaching

ASX Growth Companies With Strong Insider Backing In April 2025

Simply Wall St.

West Pharmaceutical CFO Bernard Birkett to Retire

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7508/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":846.2333,"timestamp":1746165599913,"preClose":832.1293,"halted":0,"volume":66164123,"delay":0,"changeRate":0.016949,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":14.104004,"latestTime":"05-02 16:00:00 AEST","open":828.86017,"high":847.99243,"low":828.659,"amount":212079793,"amplitude":0.023234,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1746403200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1746144000000,1746165600000]],"turnoverRate":0.001833,"increases":13,"decrements":13,"flats":17,"marketCap":134851527200.375,"floatMarketCap":132030281850},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":847.99243,"amplitude":0.023234,"preClose":832.1293,"low":828.659,"latestPrice":846.2333,"volume":66164123,"delay":0,"open":828.86017,"prevYearClose":936.801,"prevWeekClose":799.528,"prevMonthClose":827.414,"prevQuarterClose":815.605,"fiveDayClose":799.528,"twentyDayClose":818.605,"sixtyDayClose":916.519,"secType":"PLATE","market":"AU","turnoverRate":0.001833,"marketCap":134851527200.375,"floatMarketCap":132030281850,"timestamp":1746165599913,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":13,"down":12,"flat":20},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531370213","title":"Orthocell Ltd - Seeks Trading Halt Pending Announcement on  New Regulatory Approval for Remplir","url":"https://stock-news.laohu8.com/highlight/detail?id=2531370213","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531370213?lang=en_us&edition=fundamental","pubTime":"2025-04-29 09:23","pubTimestamp":1745889805,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62KP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2531429967","title":"Mesoblast Appoints Corporate Finance Leader Lyn Cobley to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2531429967","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531429967?lang=en_us&edition=fundamental","pubTime":"2025-04-29 07:44","pubTimestamp":1745883858,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nTUA6QPWHD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MSB.AU","BK7508","BK7067","BK7501"],"gpt_icon":0},{"id":"2531299972","title":"Press Release: Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2531299972","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531299972?lang=en_us&edition=fundamental","pubTime":"2025-04-29 07:44","pubTimestamp":1745883840,"startTime":"0","endTime":"0","summary":"NEW YORK, April 28, 2025  -- Mesoblast , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of Directors. Ms. Cobley has been a global leader in the financial services industry with over 30 years' experience in senior positions at international and domestic banks. Ms. Cobley has served as CEO of Westpac Institutional Bank, Group Treasurer of Commonwealth Bank of Australia, and held senior roles at Barclays Capital and Citibank Limited.Commenting on her appointment Ms. Cobley said, \"Following the recent United States Food and Drug Administration  approval of Ryoncil , Mesoblast has become a wonderful success story for not only the Australian biotechnology industry but the global leader in the allogeneic cell therapy industry. The Company has many exciting milestones in the near-term including ramp-up of commercialization and additional indications for some highly prevalent diseases. I look forward to co","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK4232","BK7508","BK4022","MSB.AU","R","BK4006","MSC","BK4139","BK7067","BK4575","MSB","BK4150","MESO"],"gpt_icon":0},{"id":"2531296544","title":"Medical Developments International Ltd -  Group Revenue for Q3 FY25 Was a$8.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2531296544","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531296544?lang=en_us&edition=fundamental","pubTime":"2025-04-29 07:20","pubTimestamp":1745882426,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nFWN3R62HG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","MVP.AU"],"gpt_icon":0},{"id":"2531298476","title":"Dimerix - Seeks Trading Halt Pending Announcement on Licensing Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2531298476","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531298476?lang=en_us&edition=fundamental","pubTime":"2025-04-29 06:32","pubTimestamp":1745879522,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nFWN3R62K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7501","BK7067","DXB.AU"],"gpt_icon":0},{"id":"2531296883","title":"3 ASX 200 stocks to buy and hold forever without thinking twice","url":"https://stock-news.laohu8.com/highlight/detail?id=2531296883","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531296883?lang=en_us&edition=fundamental","pubTime":"2025-04-29 05:52","pubTimestamp":1745877144,"startTime":"0","endTime":"0","summary":"When it comes to building lasting wealth, few strategies are as powerful — or as simple — as buy and hold investing. Instead of trying to time the market or jump in and out of ASX 200 stocks based on ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/29/3-asx-200-stocks-to-buy-and-hold-forever-without-thinking-twice/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU2237443465.HKD","BK4127","CSL.AU","LU2237443622.USD","IE0034235188.USD","IE00BSNM7G36.USD","LU2750360997.AUD","BK4504","IE00BFXG1179.USD","PME.AU","LU2750360641.GBP","IE00B19Z3B42.SGD","IE0002270589.USD","BK4588","IE00B19Z3581.USD","LU0251142724.SGD","LU2237438978.USD","BK4550","BK4552","BK4516","LU1868836591.USD","BK4585","BK7094","LU1868837136.USD","LU1868836914.USD","BK4533","LU0096364046.USD","LU1791807156.HKD","LU0742534661.SGD","LU2237443978.SGD","LU2471134523.USD","IE0004086264.USD","LU0048573561.USD","LU2237443549.SGD","IE0004091025.USD","LU1868836757.USD","LU2471134796.USD","BK7501","BK7511","LU2471134879.HKD","BK7503","LU0106831901.USD","LU0251131958.USD","LU1868837300.USD","LU1668664300.SGD","BK7067","LU2471134952.CNY","WTC.AU","BK7508","LU0061475181.USD"],"gpt_icon":0},{"id":"2531250659","title":"ASX Stocks Estimated Below Intrinsic Value In April 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531250659","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531250659?lang=en_us&edition=fundamental","pubTime":"2025-04-29 03:34","pubTimestamp":1745868879,"startTime":"0","endTime":"0","summary":"As the Australian market continues to show resilience, with the ASX200 closing up 0.36% at 7,997 points, investors are keenly observing sector performances that drive growth and stability. With sectors like Energy and IT leading gains, identifying stocks trading below their intrinsic value becomes crucial in capitalizing on potential opportunities amidst fluctuating market conditions.Top 10 Undervalued Stocks Based On Cash Flows In Australia. Overview: National Storage REIT is the largest self-storage provider in Australia and New Zealand, operating over 225 centers for more than 90,000 residential and commercial customers, with a market cap of A$3.12 billion.National Storage REIT, trading at A$2.24, is valued 35.4% below its estimated fair value of A$3.47, suggesting potential undervaluation based on cash flows. Earnings are projected to grow at 21.2% annually, surpassing the Australian market average growth rate; however, profit margins have decreased from last year’s figures and deb","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/asx-stocks-estimated-below-intrinsic-193439502.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7096","ACF.AU","GNP.AU","XKO.AU","PNV.AU","NXL.AU","NSR.AU","MVP.AU","DMP.AU","IDX.AU","BK7124","BK7088","EOS.AU","XAO.AU","BK7055","BK7151","BK7031","BK7010","BK7137","BK7016","LBL.AU","PWH.AU","BK7015","BK7126","BK7051","SLC.AU","BK7508","BK7115","XJO.AU"],"gpt_icon":0},{"id":"2531926812","title":"How Trump's tariffs have created 'upside potential' for CSL shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2531926812","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531926812?lang=en_us&edition=fundamental","pubTime":"2025-04-29 02:30","pubTimestamp":1745865000,"startTime":"0","endTime":"0","summary":"CSL Ltd (ASX: CSL) shares have gone backwards over the past year. Shares in the S&P/ASX 200 Index(ASX: XJO) biotech stock closed up 0.99% on Monday trading for $244.29. Despite that welcome boost, sha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/29/how-trumps-tariffs-have-created-upside-potential-for-csl-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","LU1169589451.USD","CSL","SGXZ23171101.USD","BK7508","BK7501","XJO.AU","LU1169590202.USD","BK7511","CSL.AU","BK4086","LU0728928796.USD","SG9999004303.SGD"],"gpt_icon":0},{"id":"2530418661","title":"BUZZ-Australia's Orthocell advances on product approval in Thailand","url":"https://stock-news.laohu8.com/highlight/detail?id=2530418661","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530418661?lang=en_us&edition=fundamental","pubTime":"2025-04-28 11:20","pubTimestamp":1745810431,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Orthocell advances on product approval in Thailand** Shares of regenerative medicine company Orthocell OCC.AX rise 7.8% to A$1.390, set for biggest one-day gain since April 10** Co says it has received regulatory approval to commence sales for its nerve repair product, Remplir, from the Food and Drug Administration in Thailand** Stock on track for third consecutive session of gains** Stock up 2.6% YTD, including current session's moves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nL4N3R6093:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","OCC.AU","BK7508"],"gpt_icon":0},{"id":"2530933654","title":"Orthocell Secures License to Sell Nerve Repair Treatment in Thailand","url":"https://stock-news.laohu8.com/highlight/detail?id=2530933654","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530933654?lang=en_us&edition=fundamental","pubTime":"2025-04-28 08:57","pubTimestamp":1745801824,"startTime":"0","endTime":"0","summary":"Orthocell  was granted a license by the Food and Drug Administration of Thailand to start selling its Remplir nerve repair collagen wrap in the country, according to a Monday Australian bourse filing.Thailand's nerve repair market has an estimated value of $84 million. It plans to appoint a local on-the-ground specialist distributor.The firm said it leveraged an expedited registration pathway available for medical devices already approved by the Health Sciences Authority in Singapore.The firm is considering other potential markets in Asia-Pacific, including Taiwan, Vietnam, Indonesia, and the Philippines.The company's shares gained about 1% in recent Monday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OCC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2530469740","title":"Orthocell Ltd -Remplir Approved to Commence Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2530469740","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530469740?lang=en_us&edition=fundamental","pubTime":"2025-04-28 06:57","pubTimestamp":1745794669,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250427:nFWN3R32HN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","OCC.AU","BK7067"],"gpt_icon":0},{"id":"2530469721","title":"Orthocell Ltd - Remplir Is NOW Approved in US, Australia, New Zealand, Singapore and Thailand","url":"https://stock-news.laohu8.com/highlight/detail?id=2530469721","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530469721?lang=en_us&edition=fundamental","pubTime":"2025-04-28 06:57","pubTimestamp":1745794669,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250427:nFWN3R32HN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2530117461","title":"Why buy and hold investing with ASX shares could be your smartest move yet","url":"https://stock-news.laohu8.com/highlight/detail?id=2530117461","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530117461?lang=en_us&edition=fundamental","pubTime":"2025-04-27 05:15","pubTimestamp":1745702100,"startTime":"0","endTime":"0","summary":"Not every company is worthy of a permanent spot in your portfolio. Investors may want to look for ASX shares with a strong competitive advantage. Does the company have something special that is hard for rivals to replicate?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/27/why-buy-and-hold-investing-with-asx-shares-could-be-your-smartest-move-yet/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","BK7067","BK7040","BK7501","WES.AU","BK7511","CBA.AU","BK7153","BK7082","BK7041","COL.AU","CSL.AU","BK7135"],"gpt_icon":0},{"id":"2530763116","title":"The 2025 stock market selloff could be a once-in-a-decade opportunity to build wealth","url":"https://stock-news.laohu8.com/highlight/detail?id=2530763116","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530763116?lang=en_us&edition=fundamental","pubTime":"2025-04-26 09:30","pubTimestamp":1745631004,"startTime":"0","endTime":"0","summary":"They say history doesn't repeat itself, but it often rhymes—and right now, the ASX is humming a very familiar tune. The kind seasoned investors know as a rare and powerful signal: opportunity. After c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/26/the-2025-stock-market-selloff-could-be-a-once-in-a-decade-opportunity-to-build-wealth/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","CSL.AU","GMG.AU","BK7099","BK7510","BK7508","BK7503","BK7046","BK7501","QLTY.AU","BK7511","TNE.AU","IVV.AU","MQG.AU","BK7155","BK7016"],"gpt_icon":0},{"id":"2530919288","title":"3 oversold ASX shares begging to rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=2530919288","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530919288?lang=en_us&edition=fundamental","pubTime":"2025-04-26 06:35","pubTimestamp":1745620500,"startTime":"0","endTime":"0","summary":"The market has been serving up a fair amount of volatility lately, and in the rush to de-risk portfolios, even some of the highest quality ASX shares have been dragged lower. But as history often show","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/26/3-oversold-asx-shares-begging-to-rebound/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IE0002270589.USD","LU1868836757.USD","BK7094","LU2237443978.SGD","IE00BFXG1179.USD","LU2237443465.HKD","BK7503","WTC.AU","IE0004086264.USD","LU2471134796.USD","LU0742534661.SGD","IE0004091025.USD","LU2237443895.HKD","LU2471134523.USD","BK4127","IE00B19Z3B42.SGD","BK4550","LU2237443382.USD","LU2471134879.HKD","BK4585","LU0251131958.USD","BK4588","BK7511","LU0096364046.USD","LU2750360997.AUD","IE0034235188.USD","LU2471134952.CNY","BK7016","BK7501","LU0061475181.USD","LU1668664300.SGD","BK4552","LU1868836591.USD","LU2237443549.SGD","PME.AU","BK4516","LU2237438978.USD","LU1868837300.USD","LU0251142724.SGD","LU2750360641.GBP","LU0106831901.USD","BK4504","LU1868837136.USD","LU2237443622.USD","CSL.AU","IE00BSNM7G36.USD","LU1868836914.USD","LU1791807156.HKD","BK7067","BK7508"],"gpt_icon":0},{"id":"2530708169","title":"NewMarket Greenlights $100 Million AMPAC Expansion; Maintains Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2530708169","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530708169?lang=en_us&edition=fundamental","pubTime":"2025-04-25 16:47","pubTimestamp":1745570838,"startTime":"0","endTime":"0","summary":"NewMarket Corp.  said Thursday it has approved up to $100 million in capital spending by its AMPAC unit to boost ammonium perchlorate production, a critical component in solid rocket motors.The expansion will include a new production line, increasing AMPAC's manufacturing capacity by more than 50%, the company said.NewMarket expects the project to be completed in 2026 and noted that it will enhance supply chain resilience.The company also maintained a quarterly dividend of $2.75 per share, payable July 1 to shareholders of record as of June 16.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4109","NEU.AU","BK7508","BK7096","NEU"],"gpt_icon":0},{"id":"2530940029","title":"ASX Penny Stocks To Watch In April 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2530940029","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530940029?lang=en_us&edition=fundamental","pubTime":"2025-04-25 11:05","pubTimestamp":1745550311,"startTime":"0","endTime":"0","summary":"The Australian market has shown resilience, with the ASX200 bouncing back to pre-tariff levels despite looming US tariffs on key sectors such as copper and pharmaceuticals. In this climate of cautious optimism, investors might find opportunities in penny stocks—companies that are smaller or newer but can offer substantial growth potential at lower price points. While the term \"penny stocks\" may seem dated, these investments continue to hold promise when supported by strong financials and robust fundamentals.Overview: Macmahon Holdings Limited offers surface and underground mining, mining support, and civil infrastructure services to mining companies in Australia and Southeast Asia, with a market cap of A$580.66 million.Operations: The company generates revenue from providing surface and underground mining, mining support, and civil infrastructure services across Australia and Southeast Asia.ASX:MAH Debt to Equity History and Analysis as at Apr 2025. Overview: Race Oncology Limited is a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/asx-penny-stocks-watch-april-030511339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["NGI.AU","BK7055","IGL.AU","BK7508","BK7095","BK7088","XAO.AU","XKO.AU","BK7045","CLX.AU","RAC.AU","RPL.AU","SHA.AU","BK7067","EZZ.AU","BK7058","MAH.AU","LBL.AU","XJO.AU","NWH.AU","GTN.AU","BIS.AU","SXE.AU","BK7062","BK7048","BK7129"],"gpt_icon":0},{"id":"2530547992","title":"Warren Buffett's warning to markets played out perfectly: the time to be greedy may be approaching","url":"https://stock-news.laohu8.com/highlight/detail?id=2530547992","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530547992?lang=en_us&edition=fundamental","pubTime":"2025-04-25 04:33","pubTimestamp":1745526780,"startTime":"0","endTime":"0","summary":"For long-term investors, periods of volatility often mark the beginning—not the end—of a wealth-building opportunity. Many quality ASX shares, from stalwarts like biotech giant CSL Ltd  and investment bank Macquarie Group Ltd  to fast-growing disruptors like health imaging technology company Pro Medicus Ltd  and online furniture and homewares retailer Temple & Webster Group Ltd , are trading at sharp discounts to what investors were willing to pay just a matter of weeks ago. If you have ve been sitting on the sidelines, waiting for the perfect moment—this may be it. Not because anyone can pick a bottom, but because, as Buffett shows time and again, value appears when investors are being fearful. So, is it time to be greedy?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/25/warren-buffetts-warning-to-markets-played-out-perfectly-the-time-to-be-greedy-may-be-approaching/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IE00BK4W5M84.HKD","LU0234570918.USD","LU0256863811.USD","BK4534","BK7508","LU0048573561.USD","BK7511","LU0980610538.SGD","IE00B1XK9C88.USD","LU0154236417.USD","IE00BWXC8680.SGD","LU0053666078.USD","LU0742534661.SGD","LU0130102774.USD","BK4585","IE00B775SV38.USD","BK4176","LU1363072403.SGD","LU1074936037.SGD","PME.AU","LU0640476718.USD","BK4550","IE000M9KFDE8.USD","IE00B3S45H60.SGD","LU0971096721.USD","BK7049","LU0251131958.USD","IE00BKDWB100.SGD","BK7046","LU0787776722.HKD","CSL.AU","BK7501","LU1571399168.USD","IE00BK4W5L77.USD","LU1366333091.USD","IE00BJLML261.HKD","BK4588","TPW.AU","LU0149725797.USD","BK4533","LU0683600562.USD","LU0417517546.SGD","LU0251142724.SGD","IE0034235303.USD","BRK.B","LU0648001328.SGD","BK7094","MQG.AU","LU0234572021.USD","BK4581"],"gpt_icon":1},{"id":"2530296775","title":"ASX Growth Companies With Strong Insider Backing In April 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2530296775","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530296775?lang=en_us&edition=fundamental","pubTime":"2025-04-25 03:38","pubTimestamp":1745523499,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a turbulent landscape marked by recent US tariffs on key sectors and fluctuating indices, investors are increasingly focused on identifying resilient growth opportunities. In this context, companies with substantial insider ownership can offer a compelling proposition, as they often signal confidence in long-term potential and alignment with shareholder interests.Top 10 Growth Companies With High Insider Ownership In Australia. Click here to see the full list of 94 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.Aussie Broadband is poised for significant earnings growth, projected at 27.6% annually, outpacing the Australian market. Despite a low forecasted return on equity of 10.8%, the company plans to expand through organic growth and mergers and acquisitions, as stated in their recent investor day. Recent board changes include Graeme Barclay joining as a Non-Executive Director, bringing extensive telecommunications e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/asx-growth-companies-strong-insider-193819249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["FLT.AU","BK7096","BK7084","BK7129","XAO.AU","BK7095","BK7093","BK7015","BK7116","UNI.AU","TTT.AU","ACR.AU","ABB.AU","BK7508","BK7077","BK7007","BK7070","NWF.AU","XKO.AU","AVA.AU","CYC.AU","FEX.AU","BK7078","IMA.AU","BBT.AU","PLT.AU","XJO.AU","BK7021","AAL.AU","BK7036"],"gpt_icon":0},{"id":"2529705932","title":"West Pharmaceutical CFO Bernard Birkett to Retire","url":"https://stock-news.laohu8.com/highlight/detail?id=2529705932","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529705932?lang=en_us&edition=fundamental","pubTime":"2025-04-24 22:18","pubTimestamp":1745504339,"startTime":"0","endTime":"0","summary":"West Pharmaceutical Services  said Thursday that Chief Financial Officer Bernard Birkett plans to retire later this year and that a search for his successor is underway.Birkett is expected to remain in the CFO role until a successor is appointed and will then serve as an advisor to support a smooth transition, the company said.West also said it appointed Shane Campbell as chief proprietary segment officer, starting May 5. Campbell most recently served as chief commercial officer of the construction materials business at Carlisle .Shares of West Pharmaceutical Services were down 3.5% in recent trading.Price: 210.50, Change: -7.68, Percent Change: -3.52","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SGXZ23171101.USD","SG9999004303.SGD","IE00B64QTZ34.USD","BK4121","BK4585","IE00BYQQ9H92.USD","CSL.AU","LU1169589451.USD","BK4588","BK7511","CSL","BK7508","BK7067","WST","BK4086","BK4567","LU0728928796.USD","LU1169590202.USD","IE00BFXG0V08.USD","BK7501","BK4504"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":92,"code":"91000000","status":"200"}]}}